Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system

Details for Australian Patent Application No. 2004317879 (hide)

Owner Celgene Corporation

Inventors Schafer, Peter H.; Zeldis, Jerome B.

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2004317879

PCT Pub. Number WO2005/094218

Priority 10/794,877 05.03.04 US

Filing date 3 September 2004

Wipo publication date 13 October 2005

International Classifications

A61K 31/553 (2006.01) - having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine

Event Publications

12 October 2006 PCT application entered the National Phase

  PCT publication WO2005/094218 Priority application(s): WO2005/094218

1 April 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004317889-Systems and methods for immobilization using selected electrodes

2004317874-Remote wire feeder